Home › Trials › NCT05106387
Clinical trial Recruiting at 8 sites Observational Ages 18 to 70

Observing kidney transplant outcomes in patients treated with vonsetamig

Official title: A Noninterventional Extension Study for Patients Treated in Study R5459-RT-1944 With Vonsetamig (BCMA x CD3 Bispecific Antibody) Who Receive a Kidney Transplant

Run by Regeneron Pharmaceuticals · NCT05106387 · Data updated 2026-11-12

This study looks at how well kidney transplants work in adults who were treated with vonsetamig before their transplant to see how it affects their health afterward.

More Chronic Kidney Disease(CKD) trials

Quick facts

Study typeObservational
Ages18 Years to 70 Years
SexAll
Enrollment20 (estimated)
SponsorRegeneron Pharmaceuticals
Industry-sponsored
Locations9 sites (Los Angeles, California and 8 other locations)
StatusRecruiting
StartedOctober 19, 2023
Main results expectedJune 14, 2027
Study endsFebruary 23, 2028
Registry record updatedSeptember 25, 2026
Trial IDNCT05106387 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults who have previously received treatment with vonsetamig and undergone a kidney transplant during the related study.

Probably not a fit

Patients who have not been treated with vonsetamig or who have not received a kidney transplant will not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to monitor the long-term outcomes of adult patients who have received a kidney transplant after being treated with vonsetamig in a previous study. Participants will be followed to assess how vonsetamig affects their health post-transplant. The study does not involve administering any new treatments, focusing instead on collecting data regarding patient health and transplant success. It is designed for individuals who have already participated in the earlier study and received a kidney transplant.

Why it matters

Potential benefit: If successful, this study could provide valuable insights into the long-term effects of vonsetamig on kidney transplant recipients.

How similar studies have gone: While this study builds on previous research involving vonsetamig, it is primarily observational and may not have direct precedents in terms of its specific focus on kidney transplant outcomes.

Who can join: the full rules

Show full inclusion / exclusion criteria 
Inclusion Criteria:

1. Received at least 1 dose of treatment with vonsetamig in study R5459-RT-1944 \[NCT05092347\].
2. Received after acceptable crossmatching, a kidney transplant while enrolled in study R5459-RT-1944
3. Willing and able to comply with clinic visits and study-related procedures
4. Provide informed consent signed by study patient or legally acceptable representative

Exclusion Criteria:

1.There are no exclusion criteria for this study.

Note: Other protocol defined Inclusion/Exclusion criteria may apply

Where it's running

  • Cedars-Sinai Medical Center
    Los Angeles, California, United States     Recruiting
  • University of California Irvine
    Orange, California, United States     Recruiting
  • Connie Frank Transplant Center at UCSF
    San Francisco, California, United States     Recruiting
  • Comprehensive Transplant Center
    Chicago, Illinois, United States     Recruiting
  • John Hopkins Hospital
    Baltimore, Maryland, United States     Recruiting
  • University of Minnesota
    Minneapolis, Minnesota, United States     Recruiting
Show 3 more locations
  • New York University Langone Health
    New York, New York, United States     Recruiting
  • Penn Transplant Institute
    Philadelphia, Pennsylvania, United States     Recruiting
  • Yale University of Medicine
    New Haven, Connecticut, United States     Completed

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov ↗ Find more trials like this →
Browse more
Chronic Kidney Disease (CKD) 9Regeneron Pharmaceuticals 70
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.